Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | BRD1 | O95696 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446781 | 0.89 | TRPV4 (0.51) | CTSLCTSSTRPA1TRPV4PHGDH | |
| SCHEMBL14342661 | 0.76 | CTSL (0.43) | CTSLCTSSTRPA1PHGDHCTSB | |
| SCHEMBL4072175 | 0.76 | CTSL (0.43) | CTSLCTSSTRPA1PHGDHCTSB | |
| SCHEMBL29590366 | 0.71 | CTSL (0.48) | CTSLCTSSTRPA1CTSBCTSK | |
| SCHEMBL14342619 | 0.71 | CTSL (0.48) | CTSLCTSSTRPA1CTSBCTSK | |
| SCHEMBL5581546 | 0.71 | CTSL (0.48) | CTSLCTSSTRPA1CTSBCTSK | |
| SCHEMBL4187902 | 0.71 | CTSL (0.46) | CTSLCTSSTRPA1CTSBCTSK | |
| SCHEMBL5447858 | 0.71 | CTSS (0.45) | CTSLCTSSTRPA1CTSBCTSK | |
| SCHEMBL5431334 | 0.71 | TRPV4 (0.73) | CTSSTRPV4CTSBCTSK | |
| SCHEMBL5434009 | 0.71 | TRPV4 (0.53) | CTSLCTSSTRPV4CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | claimed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | CTSL 1399/4885CTSS 1835/4885TRPA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.